RAAV.hPDE6A vector ( DrugBank: - )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 90 | 網膜色素変性症 | 1 |
90. 網膜色素変性症
臨床試験数 : 130 / 薬物数 : 180 - (DrugBank : 41) / 標的遺伝子数 : 49 - 標的パスウェイ数 : 109
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2016-003705-34-DE (EUCTR) | 02/07/2019 | 26/11/2018 | Administration of a genetically modified virus particle in patients with PDE6A-linked retinitis pigmentosa | PIGMENT – PDE6A gene therapy for retinitis pigmentosa | PDE6A-linked retinitis pigmentosa;Therapeutic area: Diseases [C] - Eye Diseases [C11] | Product Name: rAAV.hPDE6A vector | Universitätsklinikum Tübingen | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 9 | Human pharmacology (Phase 1): yes Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no | Germany |